With 0.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.22 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.36 whereas the lowest price it dropped to was $2.03. The 52-week range on SNGX shows that it touched its highest point at $14.92 and its lowest point at $1.83 during that stretch. It currently has a 1-year price target of $10.00. Beta for the stock currently stands at 1.84.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SNGX was down-trending over the past week, with a drop of -36.77%, but this was down by -31.42% over a month. Three-month performance dropped to -35.51% while six-month performance fell -68.43%. The stock lost -83.07% in the past year, while it has lost -15.77% so far this year.
Float and Shares Shorts:
At present, 2.51 million SNGX shares are outstanding with a float of 2.51 million shares on hand for trading. On 2024-12-31, short shares totaled 14549.0, which was 57.99999999999999 higher than short shares on 1732838400. In addition to Dr. Christopher J. Schaber Ph.D. as the firm’s Chairman of the Board of Directors, CEO & President, Mr. Jonathan L. Guarino CPA, CGMA serves as its Senior VP, CFO & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.02634 of SNGX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, SNGX reported revenue of $0.0 and operating income of -$1865236.0. The EBITDA in the recently reported quarter was -$1930666.0 and diluted EPS was -$0.78.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With SNGX analysts setting a high price target of 35.0 and a low target of 10.0, the average target price over the next 12 months is 22.5. Based on these targets, SNGX could surge 1441.85% to reach the target high and rise by 340.53% to reach the target low. Reaching the average price target will result in a growth of 891.19% from current levels.
Analysts have provided yearly estimates in a range of -$6.61421 being high and -$7.58579 being low. For SNGX, this leads to a yearly average estimate of -$7.1. Based on analyst estimates, the high estimate for the next quarter is -$1.65 and the low estimate is -$1.65. The average estimate for the next quarter is thus -$1.65.
